Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis

Savina Apolloni, Paola Fabbrizio, Chiara Parisi, Susanna Amadio, Cinzia Volonté

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Mutations in the Cu2+/Zn2+ superoxide dismutase 1 (SOD1) gene underlie 14–23 % of familial and 1–7 % of sporadic cases of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease characterized by a specific loss of motor neurons in the brain and spinal cord. Neuroinflammation and oxidative stress are emerging as key players in the pathogenesis of ALS, thus justifying the interest in glial cells and particularly microglia, in addition to motor neurons, as novel therapeutic approaches against ALS. Recently, histamine was proven to participate in the pathogenesis of neuroinflammatory and neurodegenerative diseases, and particularly, microglia was shown to be sensitive to the histamine challenge mainly through histamine H1 receptors. Clemastine is a first-generation and CNS-penetrant H1 receptor antagonist considered as a safe antihistamine compound that was shown to possess immune suppressive properties. In order to investigate if clemastine might find promising application in the treatment of ALS, in this work, we tested its action in the SOD1G93A mouse model which is extensively used in ALS preclinical studies. We demonstrated that chronic clemastine administration in SOD1G93A mice reduces microgliosis, modulates microglia-related inflammatory genes, and enhances motor neuron survival. Moreover, in vitro, clemastine is able to modify several activation parameters of SOD1G93A microglia, and particularly CD68 and arginase-1 expression, as well as phospho-ERK1/2 and NADPH oxidase 2 levels. Being clemastine a drug already employed in clinical practice, our results strongly encourage its further exploitation as a candidate for preclinical trials and a new modulator of neuroinflammation in ALS.

Original languageEnglish
Pages (from-to)518-531
Number of pages14
JournalMolecular Neurobiology
Volume53
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Clemastine
Amyotrophic Lateral Sclerosis
Microglia
Anti-Inflammatory Agents
Phenotype
Motor Neurons
Histamine H1 Receptors
Neurodegenerative Diseases
Histamine
Arginase
NADPH Oxidase
Histamine Antagonists
Neuroglia
Genes
Spinal Cord
Oxidative Stress
Neuroprotection
Mutation
Brain
Pharmaceutical Preparations

Keywords

  • Histamine H1 receptor
  • M1/M2 phenotype
  • Microglia
  • Motor neuron
  • P2X7

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. / Apolloni, Savina; Fabbrizio, Paola; Parisi, Chiara; Amadio, Susanna; Volonté, Cinzia.

In: Molecular Neurobiology, Vol. 53, No. 1, 2015, p. 518-531.

Research output: Contribution to journalArticle

@article{f1d3306f43d54cd3972ab9c8cffbcc23,
title = "Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis",
abstract = "Mutations in the Cu2+/Zn2+ superoxide dismutase 1 (SOD1) gene underlie 14–23 {\%} of familial and 1–7 {\%} of sporadic cases of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease characterized by a specific loss of motor neurons in the brain and spinal cord. Neuroinflammation and oxidative stress are emerging as key players in the pathogenesis of ALS, thus justifying the interest in glial cells and particularly microglia, in addition to motor neurons, as novel therapeutic approaches against ALS. Recently, histamine was proven to participate in the pathogenesis of neuroinflammatory and neurodegenerative diseases, and particularly, microglia was shown to be sensitive to the histamine challenge mainly through histamine H1 receptors. Clemastine is a first-generation and CNS-penetrant H1 receptor antagonist considered as a safe antihistamine compound that was shown to possess immune suppressive properties. In order to investigate if clemastine might find promising application in the treatment of ALS, in this work, we tested its action in the SOD1G93A mouse model which is extensively used in ALS preclinical studies. We demonstrated that chronic clemastine administration in SOD1G93A mice reduces microgliosis, modulates microglia-related inflammatory genes, and enhances motor neuron survival. Moreover, in vitro, clemastine is able to modify several activation parameters of SOD1G93A microglia, and particularly CD68 and arginase-1 expression, as well as phospho-ERK1/2 and NADPH oxidase 2 levels. Being clemastine a drug already employed in clinical practice, our results strongly encourage its further exploitation as a candidate for preclinical trials and a new modulator of neuroinflammation in ALS.",
keywords = "Histamine H1 receptor, M1/M2 phenotype, Microglia, Motor neuron, P2X7",
author = "Savina Apolloni and Paola Fabbrizio and Chiara Parisi and Susanna Amadio and Cinzia Volont{\'e}",
year = "2015",
doi = "10.1007/s12035-014-9019-8",
language = "English",
volume = "53",
pages = "518--531",
journal = "Molecular Neurobiology",
issn = "0893-7648",
publisher = "Humana Press Inc.",
number = "1",

}

TY - JOUR

T1 - Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis

AU - Apolloni, Savina

AU - Fabbrizio, Paola

AU - Parisi, Chiara

AU - Amadio, Susanna

AU - Volonté, Cinzia

PY - 2015

Y1 - 2015

N2 - Mutations in the Cu2+/Zn2+ superoxide dismutase 1 (SOD1) gene underlie 14–23 % of familial and 1–7 % of sporadic cases of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease characterized by a specific loss of motor neurons in the brain and spinal cord. Neuroinflammation and oxidative stress are emerging as key players in the pathogenesis of ALS, thus justifying the interest in glial cells and particularly microglia, in addition to motor neurons, as novel therapeutic approaches against ALS. Recently, histamine was proven to participate in the pathogenesis of neuroinflammatory and neurodegenerative diseases, and particularly, microglia was shown to be sensitive to the histamine challenge mainly through histamine H1 receptors. Clemastine is a first-generation and CNS-penetrant H1 receptor antagonist considered as a safe antihistamine compound that was shown to possess immune suppressive properties. In order to investigate if clemastine might find promising application in the treatment of ALS, in this work, we tested its action in the SOD1G93A mouse model which is extensively used in ALS preclinical studies. We demonstrated that chronic clemastine administration in SOD1G93A mice reduces microgliosis, modulates microglia-related inflammatory genes, and enhances motor neuron survival. Moreover, in vitro, clemastine is able to modify several activation parameters of SOD1G93A microglia, and particularly CD68 and arginase-1 expression, as well as phospho-ERK1/2 and NADPH oxidase 2 levels. Being clemastine a drug already employed in clinical practice, our results strongly encourage its further exploitation as a candidate for preclinical trials and a new modulator of neuroinflammation in ALS.

AB - Mutations in the Cu2+/Zn2+ superoxide dismutase 1 (SOD1) gene underlie 14–23 % of familial and 1–7 % of sporadic cases of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease characterized by a specific loss of motor neurons in the brain and spinal cord. Neuroinflammation and oxidative stress are emerging as key players in the pathogenesis of ALS, thus justifying the interest in glial cells and particularly microglia, in addition to motor neurons, as novel therapeutic approaches against ALS. Recently, histamine was proven to participate in the pathogenesis of neuroinflammatory and neurodegenerative diseases, and particularly, microglia was shown to be sensitive to the histamine challenge mainly through histamine H1 receptors. Clemastine is a first-generation and CNS-penetrant H1 receptor antagonist considered as a safe antihistamine compound that was shown to possess immune suppressive properties. In order to investigate if clemastine might find promising application in the treatment of ALS, in this work, we tested its action in the SOD1G93A mouse model which is extensively used in ALS preclinical studies. We demonstrated that chronic clemastine administration in SOD1G93A mice reduces microgliosis, modulates microglia-related inflammatory genes, and enhances motor neuron survival. Moreover, in vitro, clemastine is able to modify several activation parameters of SOD1G93A microglia, and particularly CD68 and arginase-1 expression, as well as phospho-ERK1/2 and NADPH oxidase 2 levels. Being clemastine a drug already employed in clinical practice, our results strongly encourage its further exploitation as a candidate for preclinical trials and a new modulator of neuroinflammation in ALS.

KW - Histamine H1 receptor

KW - M1/M2 phenotype

KW - Microglia

KW - Motor neuron

KW - P2X7

UR - http://www.scopus.com/inward/record.url?scp=84953364910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953364910&partnerID=8YFLogxK

U2 - 10.1007/s12035-014-9019-8

DO - 10.1007/s12035-014-9019-8

M3 - Article

AN - SCOPUS:84953364910

VL - 53

SP - 518

EP - 531

JO - Molecular Neurobiology

JF - Molecular Neurobiology

SN - 0893-7648

IS - 1

ER -